Gapping up
In reaction to earnings/guidance:
- ATKR +5.7%, TT +0.5%
Other news:
- MDGL +14.3% (topline clinical data from the placebo-controlled, double-blind portion of its Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom)
- TSHA +11.4% (Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy)
- MNOV +9.3% (announced that it has received a notice of allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 and MN-002 for hepatic ballooning)
- LXP +5% (to Review Letter from Land & Buildings)
- GROY +4.8% (provides an update on its growth plans and its proposed acquisition of Elemental Royalties Corp)
- IPA +4.5% (antibodies PolyTope potently neutralizes the SARS-CoV-2 Omicron Variant -- moves towards FDA/IND-submission)
- ALT +4.2% (receives FDA Clearance of Pemvidutide; Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022)
- SEV +3.8% (provides corporate update)
- MESO +2.9% (provides Appendix 4C quarterly activity report)
- NFLX +2.5% (positive Barrons article)
- OSUR +2.4% (InteliSwab COVID-19 rapid tests have been authorized by the FDA for use in children ages 2-14)
- SPOT +2.1% (issues platform rules regarding COVID-19 after some artists pull songs from service in protest over misinformation from host Joe Rogan)
- CRNT +1.4% (signed a deal with Globacom to further expand its network and enable it to maintain its technology)
- DHC +1.4% (entered into a $703 mln joint venture for 10 properties in DHC's Office Portfolio segment with two global institutional investors)
- TSLA +1.3% (positive Barrons article)
- LSEA +1% (approved a $10 million stock repurchase program)
Analyst comments:
- BYND +4.2% (upgraded to Overweight from Underweight at Barclays)
- DLO +3% (upgraded to Buy from Hold at HSBC Securities)
- BEKE +2.6% (upgraded to Hold from Reduce at HSBC Securities)
- ARCT +1.3% (upgraded to Mkt Perform from Underperform at Raymond James)
- CACI +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
- ISRG +1.1% (upgraded to Overweight from Neutral at Piper Sandler)
- GMAB +1% (upgraded to Buy from Neutral at H.C. Wainwright)
